



Supplement Material:



S1: Scanning Electron Microscopy (SEM) Images of Blank Liposomal Formulations



**S2:** Cytotoxicity of Doxorubicin Hydrochloride in Different Breast Cancer Cells;

**Table S1:** Molar ratio of Formulation Compositions

| Components | HSPC        | POPC | DOPC | DPPC | DSPE-<br>PEG-<br>2000 | Mal-<br>PEG-<br>2000 | CHO | DOPE | DOTAP | DDAB |
|------------|-------------|------|------|------|-----------------------|----------------------|-----|------|-------|------|
|            | Molar Ratio |      |      |      |                       |                      |     |      |       |      |
| F1         | 60          |      |      |      | 3                     |                      | 37  |      |       |      |
| F2         | 49          |      |      |      | 3                     | 0.03                 |     | 21   | 22    |      |
| F3         | 48          |      |      |      | 3                     | 0.03                 |     | 20   |       | 24   |
| F4         |             | 61   |      |      | 3                     |                      | 36  |      |       |      |
| F5         |             | 50   |      |      | 3                     | 0.03                 |     | 20   | 22    |      |
| F6         |             | 49   |      |      | 3                     | 0.03                 |     | 20   |       | 23   |
| F7         |             |      | 60   |      | 3                     |                      | 37  |      |       |      |
| F8         |             |      | 49   |      | 3                     | 0.03                 |     | 21   | 22    |      |
| F9         |             |      | 48   |      | 3                     | 0.03                 |     | 20   |       | 24   |
| F10        |             |      |      | 62   | 3                     |                      | 35  |      |       |      |
| F11        |             |      |      | 51   | 3                     | 0.03                 |     | 20   | 21    |      |
| F12        |             |      |      | 50   | 3                     | 0.03                 |     | 20   |       | 23   |

**Table S2:** IC<sub>50</sub> of Doxorubicin Solution and Liposomal Formulations over a period 48 h on MCF-7 and SKBR3 breast cancer cells. Data has been represented as the mean  $\pm$  SD.

| IC <sub>50</sub> ( $\mu$ M) | MCF-7           | SKBR3           |
|-----------------------------|-----------------|-----------------|
| DOX Solution                | 0.68 $\pm$ 0.03 | 0.67 $\pm$ 0.01 |
| F1                          | 0.61 $\pm$ 0.04 | 0.65 $\pm$ 0.03 |
| F2                          | 0.63 $\pm$ 0.01 | 0.59 $\pm$ 0.04 |
| F3                          | 0.42 $\pm$ 0.02 | 0.53 $\pm$ 0.03 |
| F4                          | 0.6 $\pm$ 0.02  | 0.62 $\pm$ 0.04 |
| F5                          | 0.53 $\pm$ 0.03 | 0.54 $\pm$ 0.02 |
| F6                          | 0.58 $\pm$ 0.01 | 0.58 $\pm$ 0.01 |
| F7                          | 0.57 $\pm$ 0.01 | 0.55 $\pm$ 0.01 |
| F8                          | 0.52 $\pm$ 0.02 | 0.54 $\pm$ 0.03 |
| F9                          | 0.55 $\pm$ 0.02 | 0.55 $\pm$ 0.02 |
| F10                         | 0.59 $\pm$ 0.03 | 0.54 $\pm$ 0.02 |
| F11                         | 0.56 $\pm$ 0.03 | 0.52 $\pm$ 0.03 |
| F12                         | 0.34 $\pm$ 0.01 | 0.41 $\pm$ 0.02 |

**Table S3:** Flow cytometric analysis of different formulations on MCF7 and SKBR3

breast cancer cells. \*p<0.05, \*\*p<0.01 and \*\*\*p<0.001 compared to the untreated control.

| Samples |                 | Count of Cells | Mean Fluorescence Intensity | P-value |
|---------|-----------------|----------------|-----------------------------|---------|
| MCF7    | Control         | 10,000         | $4.8 \times 10^3$           |         |
|         | Aptamer-A6-FITC | 10,000         | $4.9 \times 10^3$           | 0.1885  |
|         | F1              | 10,000         | $4.7 \times 10^3$           | 0.4226  |
|         | F5              | 10,000         | $2.4 \times 10^4$           | 0.0173  |
|         | F8              | 10,000         | $5.0 \times 10^3$           | 0.1276  |
|         | F12             | 10,000         | $5.5 \times 10^3$           | 0.5674  |
| SKBR3   | Control         | 10,000         | $3.1 \times 10^3$           |         |
|         | Aptamer-A6-FITC | 10,000         | $4.1 \times 10^3$           | 0.0815  |
|         | F1              | 10,000         | $3.8 \times 10^3$           | 0.0624  |
|         | F5              | 10,000         | $7.6 \times 10^3$           | 0.00727 |
|         | F8              | 10,000         | $3.9 \times 10^3$           | 0.0591  |
|         | F12             | 10,000         | $4.5 \times 10^3$           | 0.0459  |

**Table S4:** Flow cytometric analysis of different formulations on Her-2 positive and Her-

2 negative breast cancer cells. \*p<0.05, \*\*p<0.01 and \*\*\*p<0.001 compared to the untreated control.

| Samples |              | Count of Cells | Mean Fluorescence Intensity | P-value |
|---------|--------------|----------------|-----------------------------|---------|
| SKBR3   | Control      | 10,000         | $3.3 \times 10^3$           |         |
|         | DOX Solution | 10,000         | $2.9 \times 10^5$           | 0.0016  |
|         | DOX-NP       | 10,000         | $2.2 \times 10^4$           | 0.0032  |
|         | DOXLP (F5)   | 10,000         | $7.5 \times 10^5$           | 0.0007  |

|                   |              |        |                   |        |
|-------------------|--------------|--------|-------------------|--------|
| <b>MDA-MB-231</b> | Control      | 10,000 | $3.3 \times 10^3$ |        |
|                   | DOX Solution | 10,000 | $2.8 \times 10^5$ | 0.0020 |
|                   | DOX-NP       | 10,000 | $2.3 \times 10^4$ | 0.0027 |
|                   | DOXLP (F5)   | 10,000 | $4.2 \times 10^5$ | 0.0004 |